ClinicalTrials.gg
RecruitingNCT07625527Updated Oct 15, 2026

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

A Phase 2 interventional study of Active Surveillance and PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy in Bladder (Urothelial, Transitional Cell) Cancer and Non Muscle Invasive Bladder Cancer, sponsored by Tianjin Medical University Second Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tianjin Medical University Second Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China — 40 open to participants now, 44 under way, 10 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · China.

Planned enrollment
23rd of 47
120 · median 114
Started
2026
with 9 others
Phase 2
13 of 50
10 open now
Primary completion
2029-03
later than 35 of 43 live
Registered
44th of 50
by date
Lead sponsor
3 of 50
Tianjin Medical University Second Hospital

Among the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, this one is the 23rd largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 35 of the 43 other live ones, and was the 44th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

40 of the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

Patients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer (NMIBC) may achieve a tumor-free status after systemic immunotherapy-based bladder-sparing treatment combined with transurethral resection of bladder tumor (TURBT). However, the optimal duration of systemic immunotherapy after achieving a tumor-free status remains uncertain. Prolonged treatment may increase toxicity, treatment burden, and cost, while some patients may maintain durable disease control without continued therapy.

This randomized study aims to evaluate whether active surveillance after achieving tumor-free status is a feasible alternative to continued systemic immunotherapy in patients with extensive transurethrally unresectable very-high-risk NMIBC.

Patients will initially receive systemic immunotherapy-based treatment followed by disease evaluation using cystoscopy with biopsy and/or TURBT, urine cytology, urinary tumor DNA (utDNA), and imaging assessments. Patients who achieve tumor-free status after treatment and complete resection of visible disease will be randomized to either active surveillance or continued systemic immunotherapy.

The study will evaluate recurrence outcomes, bladder preservation, progression, safety, and patient management strategies following achievement of tumor-free status. The trial also aims to explore the role of urinary tumor DNA in identifying patients who may safely undergo treatment de-escalation and active surveillance.

03

Conditions studied

  • Bladder (Urothelial, Transitional Cell) Cancer
  • Non Muscle Invasive Bladder Cancer

Browse trials for

Keywords

  • Non-muscle-invasive bladder cancer (NMIBC)
  • Liquid biopsy
  • Immunotherapy
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

This study's planned enrollment of 120 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

Tianjin Medical University Second Hospital is the lead sponsor of 60 studies on the registry; 36 are open to participants now.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed very-high-risk non-muscle-invasive urothelial carcinoma of the bladder.
  • Has transurethrally unresectable bladder tumor, defined as visually incomplete TURBT and/or extensive high-volume disease considered unsuitable for complete and oncologically adequate transurethral resection.
  • Has undergone cystoscopy and TURBT evaluation before study enrollment.
  • Has received systemic /PD-L1 inhibitor-based bladder-sparing therapy before randomization.
  • Has achieved tumor-free status before randomization, defined as:

    1. No visible bladder tumor on cystoscopy;
    2. Negative bladder and/or TURBT pathology;
    3. Negative urine cytology;
    4. Negative urinary tumor DNA (utDNA);
    5. No radiographic evidence of progression or .
  • Has (ECOG) performance status of 0, 1, or 2.
  • Has adequate organ function.
  • Has provided written .

Cohort A Only

  • Achieved tumor-free status at the initial response evaluation after induction systemic therapy.
  • Maintained tumor-free status after additional systemic therapy before randomization.

Cohort B Only

  • Did not achieve tumor-free status at the initial response evaluation because of residual non-muscle-invasive disease.
  • Subsequently underwent complete TURBT/resection of residual disease followed by additional systemic therapy.
  • Achieved tumor-free status at the second response evaluation before randomization.

Exclusion criteria

Exclusion Criteria

  • Has muscle-invasive bladder cancer (≥T2), locally advanced unresectable disease, nodal disease, or distant .
  • Has concurrent upper tract urothelial carcinoma.
  • Has persistent visible tumor, positive bladder pathology, positive urine cytology, or positive utDNA before randomization.
  • Has received prior systemic immunotherapy for metastatic urothelial carcinoma.
  • Has active disease requiring systemic treatment.
  • Is receiving systemic therapy.
  • Has uncontrolled infection requiring systemic therapy.
  • Has another active requiring systemic treatment.
  • Has known active , , infection, or active tuberculosis.
  • Has pregnancy or breastfeeding.
  • Has any medical or psychiatric condition that, in the investigator's judgment, would interfere with study participation or interpretation of results.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Arm A-1 (Cohort A Active Surveillance)

    Patients in Cohort A who achieve early tumor-free status after initial systemic immunotherapy-based treatment will undergo active surveillance with protocol-defined cystoscopy, urine cytology, urinary tumor DNA testing, biopsy as clinically indicated, and imaging assessments.

    Behavioral: Active Surveillance

  • Active comparator
    Arm A-2 (Cohort A Continued Systemic Immunotherapy)

    Patients in Cohort A who achieve early tumor-free status after initial systemic immunotherapy-based treatment will continue systemic immunotherapy for a protocol-defined duration with ongoing disease surveillance.

    Drug: PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy

  • Experimental
    Arm B-1 (Cohort B Active Surveillance)

    Patients in Cohort B who do not achieve tumor-free status at initial evaluation but subsequently achieve tumor-free status after complete TURBT/resection and additional systemic immunotherapy will undergo active surveillance with protocol-defined surveillance assessments.

    Behavioral: Active Surveillance

  • Active comparator
    Arm B-2 (Cohort B Continued Systemic Immunotherapy)

    Patients in Cohort B who subsequently achieve tumor-free status after complete TURBT/resection and additional systemic immunotherapy will continue systemic immunotherapy for a protocol-defined duration with ongoing disease surveillance.

    Drug: PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy

Interventions

  • BehavioralActive Surveillance

    Patients undergo protocol-defined surveillance after achieving tumor-free status, including cystoscopy, biopsy as clinically indicated, urine cytology, urinary tumor DNA testing, and imaging assessments, without continued systemic PD-1/PD-L1 inhibitor therapy unless disease recurrence or progression occurs.

  • DrugPD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy

    Patients continue protocol-defined systemic PD-1/PD-L1 inhibitor therapy after achieving tumor-free status for up to approximately 1 year, with ongoing surveillance including cystoscopy, urine cytology, urinary tumor DNA testing, and imaging assessments.

07

What researchers measure

Primary outcomes

  1. Bladder-intact event-free survival (BI-EFS)

    Time from randomization to the first occurrence of high-risk NMIBC recurrence, progression to muscle-invasive bladder cancer, distant metastasis, radical cystectomy, or death from any cause.

    Time frame: Up to 2 years from randomization

Secondary outcomes

  1. Recurrence-free survival (RFS)

    Time from randomization to the first documented recurrence of bladder cancer or death from any cause.

    Time frame: Up to 2 years from randomization

  2. Progression-free survival (PFS)

    Time from randomization to progression to muscle-invasive, locally advanced, or metastatic bladder cancer, or death from any cause.

    Time frame: Up to 2 years from randomization

  3. Radical cystectomy-free survival (RCFS)

    Time from randomization to radical cystectomy or death from any cause.

    Time frame: Up to 2 years from randomization

  4. Overall survival (OS)

    Time from randomization to death from any cause.

    Time frame: Up to 2 years from randomization

  5. Incidence of treatment-related adverse events

    Proportion of patients experiencing treatment-related adverse events, graded according to CTCAE.

    Time frame: Up to 2 years from randomization

Other outcomes

  1. Recurrence-Free Survival According to Urinary Tumor DNA Status

    Recurrence-free survival will be evaluated according to urinary tumor DNA status after achieving tumor-free status. Urinary tumor DNA status will be assessed using a urine-based tumor DNA assay and categorized as positive or negative.

    Time frame: Up to 2 years from randomization

  2. utDNA conversion during surveillance

    Proportion of patients with conversion from urinary tumor DNA negative to positive during follow-up.

    Time frame: Up to 2 years from initial systemic administration

  3. Bladder-Intact Event-Free Survival According to Response Cohort in the Active Surveillance Arm

    Bladder-intact event-free survival will be compared between participants assigned to active surveillance in Cohort A and Cohort B.

    Time frame: Up to 2 years from randomization

  4. Recurrence-Free Survival According to Response Cohort in the Active Surveillance Arm

    Recurrence-free survival will be compared between participants assigned to active surveillance in Cohort A and Cohort B.

    Time frame: Up to 2 years from randomization

  5. Bladder-Intact Event-Free Survival According to Response Cohort in the Continued Systemic Immunotherapy Arm

    Bladder-intact event-free survival will be compared between participants assigned to continued systemic immunotherapy in Cohort A and Cohort B.

    Time frame: Up to 2 years from randomization

  6. Recurrence-Free Survival According to Response Cohort in the Continued Systemic Immunotherapy Arm

    Recurrence-free survival will be compared between participants assigned to continued systemic immunotherapy in Cohort A and Cohort B.

    Time frame: Up to 2 years from randomization

08

Study locations

4 of 4 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Mar 2029, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Jun 4, 2026
StartActual
May 30, 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
May 30, 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • The Second Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
  • General Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
  • Tianjin Hospital · Tianjin, Chinano status→Recruiting
  • Xingtai People's Hospital · Xingtai, Chinano status→Recruiting
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • The Second Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
    • General Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
    • Tianjin Hospital · Tianjin, Chinano status→Recruiting
    • Xingtai People's Hospital · Xingtai, Chinano status→Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07625527
Lead sponsor
Tianjin Medical University Second Hospital
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
May 30, 2026
Primary completion
Mar 30, 2029 (estimated)
Completion
May 30, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Hailong Hu, MD
Contact
huhailong@tmu.edu.cn
+8619801518556
Yunkai Qie, MD
Contact
qieyunkai@tmu.edu.cn
Hailong Hu, MD
principal investigator · Department of Urology, The Second Hospital of Tianjin Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion